Overview of WINOBOLIC Pharmaceutical Stanozolol
WINOBOLIC Pharmaceutical is a stanozolol-based oral formulation designed for laboratory research applications. Stanozolol is a synthetic anabolic steroid derived from dihydrotestosterone, featuring a pyrazole ring modification that confers unique pharmacological properties in preclinical models. This compound has been extensively studied in androgenic research for its tissue-selective anabolic activity and modified receptor binding characteristics. Researchers investigating steroid chemistry and androgen receptor modulation find stanozolol a valuable reference compound due to its well-documented pharmacokinetic profile and distinct molecular interactions compared to testosterone analogues.
The pharmaceutical-grade formulation ensures consistent research outcomes for investigators studying anabolic steroid mechanisms. Research teams at Stroid UK Shop frequently utilise stanozolol tablets for comparative studies alongside SARM compounds and peptide research materials to examine differential receptor activation pathways. The oral tablet format facilitates precise dosing for cell culture applications and enables researchers to investigate bioavailability characteristics in controlled laboratory environments.
Research Applications and Molecular Mechanisms
Stanozolol demonstrates unique binding properties at androgen receptors with reduced 5α-reductase conversion compared to testosterone. Research studies have examined its anabolic-to-androgenic ratio in tissue-selective models, making it particularly relevant for investigations into muscle protein synthesis pathways and bone mineralisation processes. The compound’s resistance to aromatisation provides researchers with a non-estrogenic steroid model for studying pure androgenic effects without confounding estrogenic activity.
Laboratory investigations have focused on stanozolol’s effects on collagen synthesis, nitrogen retention, and hepatic metabolism in cellular models. Researchers studying anabolic mechanisms appreciate the compound’s oral bioavailability, which differs significantly from injectable testosterone esters. Studies examining stanozolol metabolism reveal extensive hepatic first-pass processing, making it valuable for research into steroid biotransformation pathways and cytochrome P450 enzyme interactions. Investigators can explore how structural modifications affect steroid activity by comparing stanozolol’s pyrazole ring system against traditional steroid backbones.
Specifications and Research Parameters
| Parameter | Specification |
|---|---|
| Compound | Stanozolol tablets |
| Form | Oral tablets |
| CAS Number | 10418-03-8 |
| Molecular Formula | C₂₁H₃₂N₂O |
| Molecular Weight | 328.49 g/mol |
| Manufacturer | Pharmaceutical grade |
| Storage | Room temperature, dry environment |
| Research Use | In-vitro laboratory studies only |
The molecular structure features a 17α-methyl modification enabling oral administration while the pyrazole ring attachment at the A-ring distinguishes stanozolol from conventional testosterone derivatives. Researchers should store tablets in controlled laboratory conditions to maintain compound integrity throughout experimental periods. Oral steroid researchers value stanozolol’s stability profile and consistent pharmaceutical manufacturing standards for reproducible experimental results.
Laboratory Research Compliance
WINOBOLIC Pharmaceutical stanozolol tablets are supplied exclusively for in-vitro laboratory research purposes. This product is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must comply with institutional guidelines and relevant legislation governing anabolic steroid research materials. Proper laboratory protocols, safety procedures, and waste disposal methods must be followed when handling this research compound. All investigations should be conducted by qualified researchers within appropriate laboratory facilities designed for controlled substance research.
